Clinical Trials Directory

Trials / Unknown

UnknownNCT01166321

Carbon Ion Radiotherapy for Atypical Meningiomas

Treatment of Patients With Atypical Meningiomas Simpson Grade 4 and 5 With a Carbon Ion Boost in Combination With Postoperative Photon Radiotherapy: A Phase II Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
35 (actual)
Sponsor
University Hospital Heidelberg · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Treatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection. With this approach, local control ranges between 50 and 70%, depending on resection status. A series or smaller studies has shown that postoperative radiotherapy in this patient population can increase progression-free survival, which translates into increased overall survival. However, meningiomas are known to be radioresistant tumors, and radiation doses of 60 Gy or higher have been shown to be necessary for tumor control. Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on the cell line as well as the endpoint analyzed. First data obtained within the Phase I/II trial performed at GSI in Darmstadt on carbon ion radiotherapy for patients with high-risk meningiomas has shown safety, and treatment results are promising. Therefore, in the current Phase II-MARCIE-Study a carbon ion boost will be applied to the macroscopic tumor (gross tumor volume, GTV) in conjunction with photon radiotherapy to the clinical target volume (CTV) in patients with atypical meningiomas after incomplete resection or biopsy. Primary endpoint is progression-free survival rate, secondary endpoints are overall survival, safety and toxicity.

Conditions

Interventions

TypeNameDescription
RADIATIONCarbon Ion RadiotherapyCarbon Ion Boost 18 Gy E in single Fractions of 3 Gy E

Timeline

Start date
2012-06-01
Primary completion
2020-07-01
Completion
2026-02-01
First posted
2010-07-21
Last updated
2024-01-05

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01166321. Inclusion in this directory is not an endorsement.